Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

European journal of medicinal chemistry - 5 Sept 2018

Dalal Kush, Morin Helene, Ban Fuqiang, Shepherd Ashley, Fernandez Michael, Tam Kevin J, Li Huifang, LeBlanc Eric, Lack Nathan, Prinz Helge, Rennie Paul S, Cherkasov Artem

Abstract excerpt

The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to HEK293 Cells

Share to Molecular Structure

Share to Receptors, Androgen

Share to Small Molecule Libraries

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 30193215
DOI: 10.1016/j.ejmech.2018.08.059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.PMID 30193215Read ↗

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.Semantic proximity Read ↗

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domainSemantic proximity Read ↗

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate CancerSemantic proximity Read ↗

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.Semantic proximity Read ↗

In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate CancerSemantic proximity Read ↗

Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation.Semantic proximity Read ↗

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.Semantic proximity Read ↗

Androgen receptor antagonists: a patent review (2008-2011).Semantic proximity Read ↗

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin InteractionsSemantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

A novel small-molecule androgen receptor antagonist selective for the T878A-mutant AR in prostate cancer therapy.Semantic proximity Read ↗

A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.